Sarepta Announces FDA Approval of VYONDYS 53 for the Treatment DMD
Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved VYONDYS 53™ (golodirsen). VYONDYS 53 is an antisense oligonucleotide from Sarepta’s…
Read More...
Read More...
